65,437 trials
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Primary: Mean Hb Level of Week 20 and Week 24 — 10.61; 10.65 g/dL
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 11; 15; 11 Participants
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 67; 92; 50 Participants
Barrett's Esophagus
Primary: Change in Ki67 Biomarker Expression — 1539; 1556; 1575; 1864 cells/mm^2
Insomnia
Primary: Percentage of Overall Participants Who Transitioned to LEM at the End of the Titration Period of Core Study — 81.1 percentage of participants
Muscle Weakness
Primary: Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo — 1.3; 0.1; 1.5; 0.7 cm H2O
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Pneumococcal Infections · Pneumonia, Pneumococcal
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination With Separate V114 Lots — 10.2; 11.5; 11.0; 66.1 Percentage of participants
Schizophrenia
Primary: Number of Participants With Adverse Event and Adverse Drug Reaction — 9; 9; 11; 5 Participants
Traumatic Brain Injury
Primary: Functional Connectivity (FC) Changes Between the Left Hippocampus and Left Parietal Cortex — -0.03; 0.13; 0.02; -0.01 Change in z-transformed R-value
Knee Osteoarthritis · Arthritis
Primary: Assessment of Pain Using the Visual Analog Scale — 48.7; 62.6; 50.8; 27.1 score on a scale
Schizophrenia
Primary: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -10.4; -13.8; -14.0; -20.2 units on a scale
Anemia; Non-dialysis Dependent Chronic Kidney Disease
Primary: Mean Hb Level of Week 20 and Week 24 — 11.66; 11.93 g/dL
Non-Alcoholic Steatohepatitis (NASH)
Primary: SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F) — 41; 34; 22; 42 Participants — p==0.061
HIV · Alcohol Use · Medication Adherence
Primary: Viral Load — 3.1; 1.8; 1.8; 2.6 Log-transformed copies per. milimeter — p=0.39